Michaelis Jakob, Grabbert Markus, Sigle August, Yilmaz Mehmet, Schlager Daniel, Gratzke Christian, Miernik Arkadiusz, Schoeb Dominik Stefan
Department of Urology, Faculty of Medicine, Medical Centre, University of Freiburg, Hugstetter Str. 55, D-79106 Freiburg, Germany.
Cancers (Basel). 2022 Aug 3;14(15):3777. doi: 10.3390/cancers14153777.
To review and discuss the literature on applying tyrosine kinase inhibitors (TKIs) in the treatment of metastasised renal cell carcinoma (mRCC).
Medline, PubMed, the Cochrane database, and Embase were screened for randomised controlled trials, clinical trials, and reviews on treating renal cell carcinoma, and the role of TKI. Each substance's results were summarised descriptively.
While TKI monotherapy is not currently recommended as a first-line treatment for metastasized renal cell carcinoma, TKIs are regularly applied to treat treatment-naïve patients in combination with immunotherapy. TKIs depict the first-choice alternative therapy if immunotherapy is not tolerated or inapplicable. Currently, seven different TKIs are available to treat mRCC.
The importance of TKIs in a monotherapeutic approach has declined in the past few years. The current trend toward combination therapy for mRCC, however, includes TKIs as one significant component of treatment regimens. We found that to remain applicable to ongoing studies, both when including new substances and when testing novel combinations of established drugs. TKIs are of major importance for the treatment of renal cancer now, as well as for the foreseeable future.
回顾并讨论酪氨酸激酶抑制剂（TKIs）在转移性肾细胞癌（mRCC）治疗中的相关文献。
检索Medline、PubMed、Cochrane数据库和Embase，查找关于治疗肾细胞癌以及TKI作用的随机对照试验、临床试验和综述。对每种药物的结果进行描述性总结。
虽然目前不推荐TKI单药治疗作为转移性肾细胞癌的一线治疗方法，但TKIs常与免疫疗法联合用于初治患者。如果不耐受或不适用免疫疗法，TKIs是首选的替代疗法。目前有七种不同的TKIs可用于治疗mRCC。
在过去几年中，TKIs在单药治疗方法中的重要性有所下降。然而，目前mRCC联合治疗的趋势包括将TKIs作为治疗方案的一个重要组成部分。我们发现，无论是纳入新药物还是测试现有药物的新组合，为了适用于正在进行的研究，TKIs目前对于肾癌的治疗以及可预见的未来都至关重要。
